Par Pharmaceutical (PRX) Tops Q4 EPS by 3c
Tweet
Share
E-mailGet Alerts PRX Hot Sheet
Price: $49.98 --0%
Financial Fact:
Operating (loss) income: 45.86M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Operating (loss) income: 45.86M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Par Pharmaceutical (NYSE: PRX) reported Q4 EPS of $0.78, $0.03 better than the analyst estimate of $0.75. Revenue for the quarter came in at $253.6 million versus the consensus estimate of $230.31 million.
For earnings history and earnings-related data on Par Pharmaceutical (PRX) click here.
For earnings history and earnings-related data on Par Pharmaceutical (PRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ackman adds Netflix, Visa and Mastercard in portfolio revamp
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Aebi Schmidt Holding AG (AEBI) Reports Q2 results; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
